U.S. markets close in 3 hours 19 minutes
  • S&P 500

    3,942.38
    +0.90 (+0.02%)
     
  • Dow 30

    31,844.11
    -84.51 (-0.26%)
     
  • Nasdaq

    11,304.13
    +39.68 (+0.35%)
     
  • Russell 2000

    1,782.59
    +17.77 (+1.01%)
     
  • Crude Oil

    110.10
    +0.33 (+0.30%)
     
  • Gold

    1,843.90
    -21.50 (-1.15%)
     
  • Silver

    21.88
    -0.18 (-0.83%)
     
  • EUR/USD

    1.0662
    -0.0076 (-0.70%)
     
  • 10-Yr Bond

    2.7560
    -0.0040 (-0.14%)
     
  • GBP/USD

    1.2533
    +0.0001 (+0.01%)
     
  • USD/JPY

    127.4660
    +0.6370 (+0.50%)
     
  • BTC-USD

    29,493.07
    +180.91 (+0.62%)
     
  • CMC Crypto 200

    655.58
    -15.42 (-2.30%)
     
  • FTSE 100

    7,522.75
    +38.40 (+0.51%)
     
  • Nikkei 225

    26,677.80
    -70.34 (-0.26%)
     

Decibel Therapeutics to Present at the UBS Global Healthcare Virtual Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BOSTON, May 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will present at the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021 at 7:00 am ET.

A live webcast of the presentation may be accessed by visiting the Investors section of the Decibel Therapeutics website at https://ir.decibeltx.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the presentation.

About Decibel Therapeutics

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all. For more information about Decibel Therapeutics, please visit www.decibeltx.com/ or follow @DecibelTx.

Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.
julie.seidel@sternir.com
212-362-1200

Media Contact:
Chris Railey
Ten Bridge Communications
Chris@tenbridgecommunications.com
617-834-0936